Adhera Therapeutics, Inc.

2023 Q3 Form 10-Q Financial Statement

#000149315223029594 Filed on August 21, 2023

View on sec.gov

Income Statement

Concept 2023 Q3 2023 Q2 2022 Q2

Balance Sheet

Concept 2023 Q3 2023 Q2 2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $32.39K $58.00K $849.0K
YoY Change -75.65% -93.17% 1921.43%
Cash & Equivalents $32.39K $58.00K $849.0K
Short-Term Investments
Other Short-Term Assets $11.69K $24.00K $127.0K
YoY Change -90.5% -81.1%
Inventory
Prepaid Expenses $11.69K $24.00K $127.0K
Receivables
Other Receivables
Total Short-Term Assets $44.07K $82.00K $976.0K
YoY Change -82.78% -91.6% 2223.81%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $0.00 $0.00 $0.00
YoY Change
TOTAL ASSETS
Total Short-Term Assets $44.07K $82.00K $976.0K
Total Long-Term Assets $0.00 $0.00 $0.00
Total Assets $44.07K $82.00K $976.0K
YoY Change -82.78% -91.6% 2223.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.352M $2.318M $2.339M
YoY Change 1.72% -0.9% 2.59%
Accrued Expenses $5.546M $5.139M $3.697M
YoY Change 37.24% 39.0% 38.41%
Deferred Revenue $100.0K
YoY Change
Short-Term Debt $1.169M $1.176M $1.039M
YoY Change 4.17% 13.19% 27.17%
Long-Term Debt Due $9.660M $9.415M $6.307M
YoY Change 40.62% 49.28% 11.1%
Total Short-Term Liabilities $26.36M $22.87M $20.97M
YoY Change 19.47% 9.05% 28.01%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $26.36M $22.87M $20.97M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $26.36M $22.87M $20.97M
YoY Change 19.47% 9.05% 28.01%
SHAREHOLDERS EQUITY
Retained Earnings -$60.00M -$56.40M -$53.60M
YoY Change 8.3% 5.22%
Common Stock $31.01K $23.00K $379.0K
YoY Change 72.3% -93.93%
Preferred Stock
YoY Change
Treasury Stock (at cost) $2.000K $2.000K $2.000K
YoY Change 0.0% 0.0%
Treasury Stock Shares 119.5K shares
Shareholders Equity -$26.30M -$22.80M -$20.00M
YoY Change
Total Liabilities & Shareholders Equity $44.07K $82.00K $976.0K
YoY Change -82.78% -91.6% 2223.81%

Cashflow Statement

Concept 2023 Q3 2023 Q2 2022 Q2

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q2 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
usd
dei Entity Central Index Key
EntityCentralIndexKey
0000737207
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2022Q2 us-gaap Loan Processing Fee
LoanProcessingFee
usd
us-gaap Loan Processing Fee
LoanProcessingFee
usd
us-gaap Loan Processing Fee
LoanProcessingFee
usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
usd
ATRX Conversion Of Series E Preferred Stock To Common Stock
ConversionOfSeriesEPreferredStockToCommonStock
usd
ATRX Conversion Of Serie F Preferred Stock To Common Stock
ConversionOfSerieFPreferredStockToCommonStock
usd
ATRX Issuance Of Common Stock With Convertible Notes
IssuanceOfCommonStockWithConvertibleNotes
usd
CY2022Q2 ATRX Warrants
Warrants
usd
ATRX Warrants
Warrants
usd
ATRX Warrants
Warrants
usd
CY2022Q2 us-gaap Convertible Preferred Dividends Net Of Tax
ConvertiblePreferredDividendsNetOfTax
usd
us-gaap Convertible Preferred Dividends Net Of Tax
ConvertiblePreferredDividendsNetOfTax
usd
us-gaap Convertible Preferred Dividends Net Of Tax
ConvertiblePreferredDividendsNetOfTax
usd
CY2022Q2 us-gaap Dividends Preferred Stock Cash
DividendsPreferredStockCash
usd
us-gaap Dividends Preferred Stock Cash
DividendsPreferredStockCash
usd
us-gaap Dividends Preferred Stock Cash
DividendsPreferredStockCash
usd
CY2023Q2 ATRX Debt Instrument Unamortized Discount And Fees
DebtInstrumentUnamortizedDiscountAndFees
usd
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
shares
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
000-13789
dei Entity Registrant Name
EntityRegistrantName
ADHERA THERAPEUTICS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
11-2658569
dei Entity Address Address Line1
EntityAddressAddressLine1
8000 Innovation Parkway
dei Entity Address City Or Town
EntityAddressCityOrTown
Baton Rouge
dei Entity Address State Or Province
EntityAddressStateOrProvince
LA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
70820
dei City Area Code
CityAreaCode
(919)
dei Local Phone Number
LocalPhoneNumber
518-3748
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
4223505 shares
CY2023Q2 us-gaap Cash
Cash
58000 usd
CY2022Q4 us-gaap Cash
Cash
32000 usd
CY2023Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
24000 usd
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
47000 usd
CY2023Q2 us-gaap Assets Current
AssetsCurrent
82000 usd
CY2022Q4 us-gaap Assets Current
AssetsCurrent
79000 usd
CY2023Q2 us-gaap Assets
Assets
82000 usd
CY2022Q4 us-gaap Assets
Assets
79000 usd
CY2023Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
2318000 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2397000 usd
CY2023Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
16000 usd
CY2022Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
26000 usd
CY2023Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5139000 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4373000 usd
CY2023Q2 us-gaap Dividends Payable Current
DividendsPayableCurrent
551000 usd
CY2022Q4 us-gaap Dividends Payable Current
DividendsPayableCurrent
498000 usd
CY2023Q2 us-gaap Loans Payable Current
LoansPayableCurrent
9415000 usd
CY2022Q4 us-gaap Loans Payable Current
LoansPayableCurrent
7333000 usd
CY2023Q2 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
1176000 usd
CY2022Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
1252000 usd
CY2023Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
4254000 usd
CY2022Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
6386000 usd
CY2023Q2 us-gaap Liabilities Current
LiabilitiesCurrent
22869000 usd
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
22265000 usd
CY2023Q2 us-gaap Liabilities
Liabilities
22869000 usd
CY2022Q4 us-gaap Liabilities
Liabilities
22265000 usd
CY2023Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000 shares
CY2023Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.006
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.006
CY2023Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
180000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
180000000 shares
CY2023Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3839454 shares
CY2023Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3839454 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
3160877 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
3160877 shares
CY2023Q2 us-gaap Common Stock Value
CommonStockValue
23000 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
19000 usd
CY2023Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
33610000 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
33548000 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-56418000 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-55751000 usd
CY2023Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
5594 shares
CY2022Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
5594 shares
CY2023Q2 us-gaap Treasury Stock Value
TreasuryStockValue
2000 usd
CY2022Q4 us-gaap Treasury Stock Value
TreasuryStockValue
2000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-22787000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-22186000 usd
CY2023Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
82000 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
79000 usd
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
296000 usd
CY2022Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
449000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
648000 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
709000 usd
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
296000 usd
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
449000 usd
us-gaap Operating Expenses
OperatingExpenses
648000 usd
us-gaap Operating Expenses
OperatingExpenses
709000 usd
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-296000 usd
CY2022Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-449000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-648000 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-709000 usd
CY2023Q2 us-gaap Interest Expense Other
InterestExpenseOther
357000 usd
CY2022Q2 us-gaap Interest Expense Other
InterestExpenseOther
361000 usd
us-gaap Interest Expense Other
InterestExpenseOther
692000 usd
us-gaap Interest Expense Other
InterestExpenseOther
672000 usd
CY2023Q2 ATRX Initial And Change In Fair Value Of Derivative Liability
InitialAndChangeInFairValueOfDerivativeLiability
1742000 usd
CY2022Q2 ATRX Initial And Change In Fair Value Of Derivative Liability
InitialAndChangeInFairValueOfDerivativeLiability
1012000 usd
ATRX Initial And Change In Fair Value Of Derivative Liability
InitialAndChangeInFairValueOfDerivativeLiability
2459000 usd
ATRX Initial And Change In Fair Value Of Derivative Liability
InitialAndChangeInFairValueOfDerivativeLiability
1679000 usd
CY2023Q2 us-gaap Loan Processing Fee
LoanProcessingFee
462000 usd
us-gaap Loan Processing Fee
LoanProcessingFee
809000 usd
CY2023Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
36000 usd
CY2022Q2 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
210000 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
75000 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
215000 usd
CY2023Q2 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
392000 usd
CY2022Q2 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
313000 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
1000000 usd
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
488000 usd
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
567000 usd
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
548000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
33000 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
734000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
271000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
99000 usd
us-gaap Net Income Loss
NetIncomeLoss
-615000 usd
us-gaap Net Income Loss
NetIncomeLoss
25000 usd
CY2023Q2 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
26000 usd
CY2022Q2 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
406000 usd
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
53000 usd
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
566000 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
245000 usd
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-307000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-668000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-541000 usd
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.07
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.27
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.20
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.27
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3462539 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1140083 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3260540 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2003921 shares
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.27
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.20
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.27
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
98538396 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1140083 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3260540 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2003921 shares
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-25106000 usd
CY2022Q1 us-gaap Dividends
Dividends
364000 usd
CY2022Q1 ATRX Stock Issued During Period Value Conversion With Convertible Note
StockIssuedDuringPeriodValueConversionWithConvertibleNote
18000 usd
CY2022Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
28000 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-74000 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-25498000 usd
CY2022Q2 us-gaap Dividends
Dividends
202000 usd
CY2022Q2 ATRX Stock Issued During Period Value Issuance Of Common Stock With Term Loan
StockIssuedDuringPeriodValueIssuanceOfCommonStockWithTermLoan
11000 usd
CY2022Q2 ATRX Stock Issued During Period Value Conversion Of Series E Preferred Stock For Common Stock
StockIssuedDuringPeriodValueConversionOfSeriesEPreferredStockForCommonStock
5056000 usd
CY2022Q2 ATRX Stock Issued During Period Value Conversion Of Series F Preferred Stock For Common Stock
StockIssuedDuringPeriodValueConversionOfSeriesFPreferredStockForCommonStock
541000 usd
CY2022Q2 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
2000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
99000 usd
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-19995000 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-22186000 usd
CY2023Q1 us-gaap Dividends
Dividends
26000 usd
CY2023Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
5000 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-886000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-23093000 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-23093000 usd
CY2023Q2 us-gaap Dividends
Dividends
26000 usd
CY2023Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
61000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
271000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-22787000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-22787000 usd
us-gaap Net Income Loss
NetIncomeLoss
-615000 usd
us-gaap Net Income Loss
NetIncomeLoss
25000 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
1000000 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
488000 usd
us-gaap Interest Expense Other
InterestExpenseOther
692000 usd
us-gaap Interest Expense Other
InterestExpenseOther
672000 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
2459000 usd
us-gaap Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
1679000 usd
us-gaap Loan Processing Fee
LoanProcessingFee
809000 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
75000 usd
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
215000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-23000 usd
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
7000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-89000 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
30000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
88000 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-4000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-626000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-690000 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
805000 usd
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
2200000 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
58000 usd
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
328000 usd
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
2000 usd
us-gaap Repayments Of Debt
RepaymentsOfDebt
95000 usd
us-gaap Repayments Of Debt
RepaymentsOfDebt
407000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
652000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1463000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
26000 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
773000 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
32000 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
76000 usd
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
58000 usd
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
849000 usd
us-gaap Interest Paid Net
InterestPaidNet
4000 usd
us-gaap Interest Paid Net
InterestPaidNet
81000 usd
ATRX Conversion Of Series E Preferred Stock To Common Stock
ConversionOfSeriesEPreferredStockToCommonStock
5056000 usd
ATRX Conversion Of Serie F Preferred Stock To Common Stock
ConversionOfSerieFPreferredStockToCommonStock
541000 usd
ATRX Debt Discounts For Issuance Costs Warrants And Derivatives
DebtDiscountsForIssuanceCostsWarrantsAndDerivatives
407000 usd
ATRX Debt Discounts For Issuance Costs Warrants And Derivatives
DebtDiscountsForIssuanceCostsWarrantsAndDerivatives
10000 usd
us-gaap Stock Issued1
StockIssued1
4000 usd
us-gaap Stock Issued1
StockIssued1
28000 usd
ATRX Issuance Of Common Stock With Convertible Notes
IssuanceOfCommonStockWithConvertibleNotes
20000 usd
ATRX Accrued Dividends
AccruedDividends
53000 usd
ATRX Accrued Dividends
AccruedDividends
566000 usd
CY2021Q4 ATRX License Agreement Commitments Description
LicenseAgreementCommitmentsDescription
On November 17, 2021, Melior I extended the Company’s timeline from 120 days to 180 days from the effective of the MLR-1023 Agreement for the Raise Requirement, if by 180 days Adhera is in the process of completing transactions to complete the fundraising then an additional 30 days shall be provided to allow for the completion of required fundraising.
CY2023Q2 us-gaap Cash
Cash
58000 usd
CY2023Q2 ATRX Working Capital
WorkingCapital
22800000 usd
us-gaap Net Income Loss
NetIncomeLoss
-615000 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-626000 usd
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-22800000 usd
CY2023Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-56400000 usd
CY2022Q4 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
1-for-20 reverse stock split
CY2023Q2 us-gaap Cash
Cash
58000 usd
us-gaap Use Of Estimates
UseOfEstimates
<p id="xdx_84C_eus-gaap--UseOfEstimates_z2zltWc1fWNl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zFlRU8ZWAeRg">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of the accompanying consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reported period. Significant areas requiring the use of management estimates include accruals related to our operating activity including legal and other consulting expenses, the fair value of non-cash equity-based issuances, the fair value of derivative liabilities, and the valuation allowance on deferred tax assets. Actual results could differ materially from such estimates under different assumptions or circumstances.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>ADHERA THERAPEUTICS, INC. AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CONDENSED NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>FOR THE SIX MONTHS ENDED JUNE 30, 2023 and 2022</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>(unaudited)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q2 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
4254000 usd
CY2023Q2 us-gaap Derivative Fair Value Of Derivative Liability
DerivativeFairValueOfDerivativeLiability
4254000 usd
CY2022Q4 us-gaap Derivative Assets Liabilities At Fair Value Net
DerivativeAssetsLiabilitiesAtFairValueNet
6386000 usd
ATRX Initial Valuation Of Derivative Liabilities Included In Debt Discount
InitialValuationOfDerivativeLiabilitiesIncludedInDebtDiscount
407000 usd
ATRX Initial Valuation Of Derivative Liabilities Included In Derivative Expense
InitialValuationOfDerivativeLiabilitiesIncludedInDerivativeExpense
565000 usd
ATRX Reclassification Of Derivative Liabilities To Gain On Debt Extinguishment
ReclassificationOfDerivativeLiabilitiesToGainOnDebtExtinguishment
-80000 usd
ATRX Change In Fair Value Included In Derivative Expense Income
ChangeInFairValueIncludedInDerivativeExpenseIncome
-3024000 usd
CY2023Q2 us-gaap Derivative Assets Liabilities At Fair Value Net
DerivativeAssetsLiabilitiesAtFairValueNet
4254000 usd
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
271000 usd
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
99000 usd
us-gaap Net Income Loss
NetIncomeLoss
-615000 usd
us-gaap Net Income Loss
NetIncomeLoss
25000 usd
CY2023Q2 us-gaap Dividends Preferred Stock
DividendsPreferredStock
26000 usd
CY2022Q2 us-gaap Dividends Preferred Stock
DividendsPreferredStock
406000 usd
us-gaap Dividends Preferred Stock
DividendsPreferredStock
53000 usd
us-gaap Dividends Preferred Stock
DividendsPreferredStock
566000 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
245000 usd
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-307000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-668000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-541000 usd
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3462539 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1140083 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3260540 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2003921 shares
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.07
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.27
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.20
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.27
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
245000 usd
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-307000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-668000 usd
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-541000 usd
CY2023Q2 us-gaap Dividends Preferred Stock Stock
DividendsPreferredStockStock
26000 usd
CY2023Q2 us-gaap Interest Expense Other Long Term Debt
InterestExpenseOtherLongTermDebt
59000 usd
CY2023Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1742000 usd
CY2023Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-1412000 usd
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-307000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-668000 usd
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-541000 usd
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3462539 shares
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1140083 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3260540 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
2003921 shares
CY2023Q2 ATRX Warrants
Warrants
33292474000 usd
CY2023Q2 us-gaap Convertible Preferred Dividends Net Of Tax
ConvertiblePreferredDividendsNetOfTax
61591569000 usd
CY2023Q2 us-gaap Dividends Preferred Stock Cash
DividendsPreferredStockCash
191814000 usd
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
98538396 shares
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1140083 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3260540 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
2003921 shares
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.27
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.20
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.27
CY2023Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
34393981 shares
CY2022Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7775716 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
129469838 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7775716 shares
CY2023Q2 us-gaap Prepaid Expense Current And Noncurrent
PrepaidExpenseCurrentAndNoncurrent
24000 usd
CY2022Q4 us-gaap Prepaid Expense Current And Noncurrent
PrepaidExpenseCurrentAndNoncurrent
47000 usd
CY2023Q2 us-gaap Notes Payable
NotesPayable
10055000 usd
CY2022Q4 us-gaap Notes Payable
NotesPayable
8042000 usd
CY2023Q2 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
640000 usd
CY2022Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
709000 usd
CY2023Q2 us-gaap Loans Payable
LoansPayable
9415000 usd
CY2022Q4 us-gaap Loans Payable
LoansPayable
7333000 usd
CY2022Q4 us-gaap Debt Instrument Description
DebtInstrumentDescription
(i) the 12-month anniversary of the original issuance date of the Notes, or December 14, 2023, (ii) a financing transaction which results in the Company’s common stock being listed on a national securities exchange, and (iii) an event of default. If an event of default occurs before the Company’s common stock is listed on a national securities exchange, the event of default would require a repayment of 125% of the outstanding principal, accrued interest and other amounts owing thereon unless the Company is trading on a national securities exchange in which case the repayment would be 100%. The Notes bear interest at 8% per annum, subject to an increase to 15% in case of an event of default as provided for therein. In addition, at any time before the 12-month anniversary of the date of issuance of the Notes, the Company may, upon five days’ prior written notice to the Purchaser, prepay all of the then outstanding principal amount of the Notes for cash in an amount equal to the sum of 105% of all amounts due and owing hereunder, including all accrued and unpaid interest.
CY2023Q1 us-gaap Debt Instrument Description
DebtInstrumentDescription
the 12-month anniversary of the original issuance date of the Notes, or January 18, 2024, (ii) a financing transaction which results in the Company’s common stock being listed on a national securities exchange, and (iii) an event of default. If an event of default occurs before the Company’s common stock is listed on a national securities exchange, the event of default would require a repayment of 125% of the outstanding principal, accrued interest and other amounts owing thereon unless the Company is trading on a national securities exchange in which case the repayment would be 100%. The Notes bear interest at 8% per annum, subject to an increase to 15% in case of an event of default as provided for therein. In addition, at any time before the 12-month anniversary of the date of issuance of the Notes, the Company may, upon five days’ prior written notice to the Purchaser, prepay all of the then outstanding principal amount of the Notes for cash in an amount equal to the sum of 105% of all amounts due and owing hereunder, including all accrued and unpaid interest.
CY2023Q2 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
1176000 usd
CY2022Q4 us-gaap Convertible Notes Payable
ConvertibleNotesPayable
1319000 usd
CY2022Q4 ATRX Debt Instrument Unamortized Discount And Fees
DebtInstrumentUnamortizedDiscountAndFees
67000 usd
CY2023Q2 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
1176000 usd
CY2022Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
1252000 usd
CY2023Q2 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
1671294 usd
CY2022Q1 us-gaap Debt Conversion Original Debt Interest Rate Of Debt
DebtConversionOriginalDebtInterestRateOfDebt
0.16 pure
CY2022Q3 us-gaap Debt Conversion Original Debt Interest Rate Of Debt
DebtConversionOriginalDebtInterestRateOfDebt
0.18 pure
CY2021 ATRX Reclassification Of Additional Paid In Capital To Derivative Liability
ReclassificationOfAdditionalPaidInCapitalToDerivativeLiability
3462000 usd
CY2023Q2 ATRX Royalities Due Liabilities Current
RoyalitiesDueLiabilitiesCurrent
24500 usd
CY2022Q4 ATRX Royalities Due Liabilities Current
RoyalitiesDueLiabilitiesCurrent
24500 usd
CY2023Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
100000 shares
CY2022Q4 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
6785914 shares
us-gaap Stock Issued During Period Shares Conversion Of Convertible Securities
StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
12487902 shares
us-gaap Stock Issued During Period Shares Conversion Of Units
StockIssuedDuringPeriodSharesConversionOfUnits
43121004 shares
us-gaap Stock Issued During Period Shares Other
StockIssuedDuringPeriodSharesOther
4670301 shares
ATRX Share Based Compensation Arrangement By Share Based Payment Award Warrants Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardWarrantsExpirationsInPeriod
1520280 shares
CY2023Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
65544841 shares
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
1600000 usd
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
19000000 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
19.60
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
19000000 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
19.60
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0 shares

Files In Submission

Name View Source Status
0001493152-23-029594-index-headers.html Edgar Link pending
0001493152-23-029594-index.html Edgar Link pending
0001493152-23-029594.txt Edgar Link pending
0001493152-23-029594-xbrl.zip Edgar Link pending
atrx-20230630.xsd Edgar Link pending
ex31-1.htm Edgar Link pending
ex31-2.htm Edgar Link pending
ex32-1.htm Edgar Link pending
ex32-2.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
form10-q.htm Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
atrx-20230630_cal.xml Edgar Link unprocessable
atrx-20230630_lab.xml Edgar Link unprocessable
atrx-20230630_def.xml Edgar Link unprocessable
atrx-20230630_pre.xml Edgar Link unprocessable
form10-q_htm.xml Edgar Link completed
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending